KPTI
NASDAQ · Biotechnology
Karyopharm Therapeutics Inc
$8.90
+0.05 (+0.57%)
Open$9.53
Previous Close$8.85
Day High$10.23
Day Low$8.70
52W High$10.99
52W Low$3.65
Volume—
Avg Volume410.7K
Market Cap200.64M
P/E Ratio—
EPS$-16.60
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+452.1% upside
Current
$8.90
$8.90
Target
$49.14
$49.14
$31.72
$49.14 avg
$61.64
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 301.13M | 308.53M | 24.30M |
| Net Income | -404,149,781 | -372,679,101 | -4,467,152 |
| Profit Margin | -134.2% | -127.5% | -18.4% |
| EBITDA | -314,646,059 | -306,264,094 | -5,147,496 |
| Free Cash Flow | — | — | -3,231,735 |
| Rev Growth | -2.4% | -2.4% | +18.6% |
| Debt/Equity | 3.78 | 3.78 | 0.75 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |